 The primary efficacy objective of this study is to compare the coefficient of fat absorption CFA following oral administration of Aptalis Pharmas formerly Eurand Pharmaceuticals pancreatic enzyme product PEP capsules and placebo in participants with cystic fibrosis CF and exocrine pancreatic insufficiency EPI. 